Adagene Inc ADR ADAG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.41
- Day Range
- $2.28–2.54
- 52-Week Range
- $1.10–4.01
- Bid/Ask
- $2.31 / $2.40
- Market Cap
- $102.00 Mil
- Volume/Avg
- 25,734 / 22,606
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.59
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 174
- Website
- https://www.adagene.com
Valuation
|
Metric
|
ADAG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.44 |
Price/Sales | 5.59 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADAG
|
|---|---|
Quick Ratio | 3.50 |
Current Ratio | 3.61 |
Interest Coverage | −18.44 |
Quick Ratio
ADAG
Profitability
|
Metric
|
ADAG
|
|---|---|
Return on Assets (Normalized) | −8.68% |
Return on Equity (Normalized) | −14.81% |
Return on Invested Capital (Normalized) | −14.28% |
Return on Assets
ADAG
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rnnskbvqb | Fzhz | $547.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mlpvwvjkb | Rbdpgp | $105.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ndmxktd | Sdtlhz | $103.7 Bil | |
MRNA
| Moderna Inc | Sshwcwkw | Cvfv | $46.8 Bil | |
ARGX
| argenx SE ADR | Ncgcjwwmw | Wtwxk | $23.2 Bil | |
BNTX
| BioNTech SE ADR | Jylrljrb | Hsdz | $22.5 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dfjlzhws | Rnbrc | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fpphkjdp | Kbjsbt | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xbgklcxfv | Vyfcd | $12.8 Bil | |
INCY
| Incyte Corp | Wzbkzynq | Yyjkndj | $12.1 Bil |